Ariceum Unveils Promising Data on 225Ac-Satoreotide at EANM 2024

Ariceum Therapeutics, a private biotechnology company focused on developing radiopharmaceutical products for diagnosing and treating challenging cancers, presented groundbreaking data on its radiolabelled peptide SS0110, known as satoreotide, at the European Association of Nuclear Medicine (EANM) Annual Conference in Hamburg, Germany, from October 19-23, 2024. Satoreotide is a pioneering antagonist of the somatostatin receptor 2 (SSTR2) and marks the first such antagonist labelled with 225Ac to enter clinical trials. The company showcased its findings during a well-received oral presentation titled "225Ac-SSO110 induces long-lasting anti-tumour responses in contrast to 225Ac-DOTA-TATE and 161Tb-DOTA-TATE in the treatment of SSTR2-positive tumour xenografts."

The data presented compared the anti-tumour efficacy of different radiolabelled satoreotide antagonists (225Ac, 161Tb, 177Lu-labelled SSO110) against corresponding DOTA-TATE agonists (225Ac and 161Tb-labelled DOTA-TATE). The study was conducted on mice engrafted with SSTR2 positive xenografts of small cell lung cancer (SCLC) and pancreatic cancer. The results revealed that 225Ac-satoreotide demonstrated superior anti-tumour efficacy at a low single dose compared to the DOTA-TATE variants, regardless of the radionuclide used. Satoreotide consistently showed greater pre-clinical anti-tumour efficacy than DOTA-TATE, which required higher dose levels to achieve similar effects.

The presentation emphasized that satoreotide was well tolerated across various doses and radionuclides. These findings are expected to guide further clinical development of satoreotide for multiple SSTR2-expressing cancers, including SCLC, pancreatic cancers, and Merkel Cell Carcinoma (MCC). Previous comparisons have indicated that 225Ac-satoreotide is significantly more potent than the SSTR2 agonist 225Ac-DOTA-TATE, achieving a complete and durable response in murine xenograft models of SCLC.

In past presentations, Ariceum had also highlighted that 212Pb was not pursued due to its greater side effects compared to Lutetium or Terbium, despite not showing increased potency. Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, expressed confidence in satoreotide's potential, noting its superior efficacy in tumour growth control and high frequency of complete durable responses, especially when a single dose of 30 kBq 225Ac-satoreotide was administered. He emphasized the strong support for further clinical development of satoreotide in treating SCLC, MCC, and potentially other cancers.

Ariceum Therapeutics, headquartered in Berlin, operates globally with additional offices in Germany, Switzerland, Australia, the United Kingdom, and the United States. The company, launched in 2021, acquired all rights to Satoreotide from Ipsen, which remains a shareholder. Ariceum is supported by experienced management and specialist investors, including EQT Life Sciences, HealthCap, Pureos Bioventures, Andera Partners, and Earlybird Venture Capital.

The European Association of Nuclear Medicine (EANM) is a non-profit organization dedicated to promoting nuclear medicine to improve public health. EANM aims to advance nuclear medicine through personalized healthcare, innovative diagnostic and therapeutic techniques, and increasing awareness of the field.